Identification

Name
Ondansetron
Accession Number
DB00904  (APRD00481)
Type
Small Molecule
Groups
Approved
Description

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. [PubChem]

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Ondansetron hydrochloride2999F27MAD99614-01-4MKBLHFILKIKSQM-UHFFFAOYSA-N
Ondansetron hydrochloride dihydrateNMH84OZK2B103639-04-9VRSLTNZJOUZKLX-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act OndansetronTablet8 mgOralActavis Pharma Company2009-06-29Not applicableCanada
Act OndansetronTablet4 mgOralActavis Pharma Company2009-06-29Not applicableCanada
Ag-ondansetronTablet8 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-ondansetronTablet4 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ava-ondansetronTablet8 mgOralAvanstra Inc2011-08-182016-09-02Canada
Bio-ondansetronTablet4 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-ondansetronTablet8 mgOralBiomed PharmaNot applicableNot applicableCanada
Ccp-ondansetronTablet4 mgOralCellchem Pharmaceuticals Inc.2017-07-24Not applicableCanada
Ccp-ondansetronTablet8 mgOralCellchem Pharmaceuticals Inc.2017-07-24Not applicableCanada
Dom-ondansetronTablet4 mgOralDominion Pharmacal2008-04-17Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ondansetronTablet8 mgOralApotex Corporation2006-11-16Not applicableCanada
Apo-ondansetronTablet4 mgOralApotex Corporation2006-11-16Not applicableCanada
OndansetronTablet, orally disintegrating4 mg/1OralPd Rx Pharmaceuticals, Inc.2007-08-02Not applicableUs
OndansetronTablet, orally disintegrating4 mg/1OralClinical Solutions Wholsesale2007-08-31Not applicableUs
OndansetronInjection, solution4 mg/2mLIntramuscular; IntravenousFresenius Kabi2013-08-23Not applicableUs
OndansetronTablet, orally disintegrating8 mg/1OralAidarex Pharmaceuticals LLC2007-06-27Not applicableUs68462 0158 13 nlmimage10 e440f267
OndansetronTablet, film coated4 mg/1OralA S Medication Solutions2007-06-252017-06-20Us
OndansetronTablet, orally disintegrating4 mg/1OralNucare Pharmaceuticals, Inc.2007-06-27Not applicableUs
OndansetronSolution4 mg/5mLOralAtlantic Biologicals Corps.2010-12-17Not applicableUs
OndansetronSolution4 mg/5mLOralNorth Star Rx Llc2007-11-28Not applicableUs
International/Other Brands
Zofran odt / Zophren
Categories
UNII
4AF302ESOS
CAS number
99614-02-5
Weight
Average: 293.363
Monoisotopic: 293.152812245
Chemical Formula
C18H19N3O
InChI Key
FELGMEQIXOGIFQ-UHFFFAOYSA-N
InChI
InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3
IUPAC Name
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one
SMILES
CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2

Pharmacology

Indication

For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, postoperation, and radiation. Also used for the treatment of postoperative nausea and vomiting.

Structured Indications
Pharmacodynamics

Ondansetron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors. The serontonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting.

Mechanism of action

Ondansetron is a selective serotonin 5-HT3 receptor antagonist. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.

TargetActionsOrganism
A5-hydroxytryptamine receptor 3A
antagonist
Human
U5-hydroxytryptamine receptor 4
agonist
Human
UMu-type opioid receptor
other/unknown
Human
U5-hydroxytryptamine receptor 1A
other/unknown
Human
U5-hydroxytryptamine receptor 1B
other/unknown
Human
Absorption

Ondansetron is well absorbed after oral administration and undergoes limited first-pass metabolism.

Volume of distribution
Not Available
Protein binding

70%-76% (Plasma protein binding)

Metabolism

Hepatic

Route of elimination
Not Available
Half life

5.7 hours

Clearance
  • 0.38 L/h/kg [Normal Adult Volunteers (19-40 yrs)]
  • 0.32 L/h/kg [Normal Adult Volunteers (61-74 yrs)]
  • 0.26 L/h/kg [Normal Adult Volunteers (>=75 yrs)]
Toxicity

Low blood pressure and fainting, sudden blindness, severe constipation

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*1xN,Not AvailableGene duplication.Effect Directly StudiedPatients with this genotype in CYP2D6 are ultrarapid metabolizers with an increased risk of poor therapeutic response and vomiting when treated with ondansteron.Details
Cytochrome P450 2D6CYP2D6*2xNNot AvailableGene duplication.Effect Directly StudiedPatients with this genotype in CYP2D6 are ultrarapid metabolizers with an increased risk of poor therapeutic response and vomiting when treated with ondansteron.Details
Cytochrome P450 2D6CYP2D6*1XNNot AvailableNormal allele duplicated.ADR InferredUltra-rapid drug metabolizer. Risk of toxicity, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*2XNNot Available2850C>T / 4180G>C  … show all ADR InferredUltra-rapid drug metabolizer. Risk of toxicity, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*1XNNot AvailableNormal allele duplicated.Effect InferredPoor responseDetails

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineOndansetron may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineOndansetron may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineOndansetron may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ondansetron is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Ondansetron can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Ondansetron is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ondansetron.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Allopregnanolone.Investigational
AlmotriptanOndansetron may increase the serotonergic activities of Almotriptan.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ondansetron.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Ondansetron.Approved
AmiodaroneThe metabolism of Ondansetron can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Ondansetron.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ondansetron.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Ondansetron.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Amperozide.Experimental
AmphetamineOndansetron may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AnagrelideOndansetron may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineOndansetron may increase the hypotensive activities of Apomorphine.Approved, Investigational
AprepitantThe serum concentration of Ondansetron can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
Arsenic trioxideOndansetron may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Ondansetron can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ondansetron.Approved
AtazanavirThe metabolism of Ondansetron can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Ondansetron.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Azaperone.Vet Approved
AzelastineOndansetron may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Ondansetron.Approved
BaclofenThe risk or severity of adverse effects can be increased when Ondansetron is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Ondansetron is combined with Barbital.Illicit
BedaquilineOndansetron may increase the QTc-prolonging activities of Bedaquiline.Approved
BenperidolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Benzocaine.Approved
BenzphetamineOndansetron may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ondansetron is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Ondansetron can be decreased when combined with Betaxolol.Approved
BoceprevirThe metabolism of Ondansetron can be decreased when combined with Boceprevir.Withdrawn
BortezomibBortezomib may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
BosentanThe serum concentration of Ondansetron can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ondansetron is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ondansetron.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Ondansetron is combined with Bromisoval.Experimental
BromocriptineOndansetron may increase the serotonergic activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ondansetron.Approved, Investigational
BuprenorphineOndansetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Ondansetron can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Ondansetron.Approved
BuspironeOndansetron may increase the serotonergic activities of Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ondansetron.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Ondansetron is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ondansetron is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Ondansetron is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ondansetron.Approved, Illicit, Vet Approved
CabergolineOndansetron may increase the serotonergic activities of Cabergoline.Approved
CaffeineThe metabolism of Ondansetron can be decreased when combined with Caffeine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Ondansetron is combined with Canertinib.Investigational
CapecitabineThe metabolism of Ondansetron can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Ondansetron can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Ondansetron is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Carisoprodol.Approved
CelecoxibThe metabolism of Ondansetron can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Ondansetron can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ondansetron.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chloroprocaine.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Ondansetron.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlorphenamine.Approved
ChlorphentermineOndansetron may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Ondansetron.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Ondansetron can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Ondansetron can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Ondansetron can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ondansetron.Approved, Vet Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
CisaprideOndansetron may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramOndansetron may increase the serotonergic activities of Citalopram.Approved
ClarithromycinOndansetron may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Ondansetron can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clidinium.Approved
ClobazamThe metabolism of Ondansetron can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Ondansetron is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Ondansetron.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ondansetron.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Ondansetron can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Ondansetron.Approved
CobicistatThe serum concentration of Ondansetron can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Ondansetron can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ondansetron.Approved, Illicit
ConivaptanThe serum concentration of Ondansetron can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Ondansetron can be decreased when combined with Crisaborole.Approved
CrizotinibOndansetron may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Cyclizine.Approved
CyclobenzaprineOndansetron may increase the serotonergic activities of Cyclobenzaprine.Approved
CyclosporineThe metabolism of Ondansetron can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Ondansetron can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Ondansetron can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ondansetron.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Ondansetron can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Ondansetron can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ondansetron can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ondansetron can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Ondansetron.Approved
DelavirdineThe metabolism of Ondansetron can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Ondansetron.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Ondansetron.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Desloratadine.Approved, Investigational
DesvenlafaxineOndansetron may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ondansetron.Approved, Vet Approved
DextroamphetamineOndansetron may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanOndansetron may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ondansetron.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ondansetron.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Ondansetron is combined with Diethyl ether.Experimental
DiethylpropionOndansetron may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ondansetron.Approved, Illicit
DihydroergotamineThe metabolism of Ondansetron can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Ondansetron can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dimenhydrinate.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Ondansetron.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ondansetron.Approved, Illicit
DisopyramideOndansetron may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dixyrazine.Experimental
DofetilideOndansetron may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Ondansetron.Approved
DomperidoneOndansetron may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Ondansetron can be decreased when combined with Dosulepin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Ondansetron.Approved
DoxycyclineThe metabolism of Ondansetron can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ondansetron is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved, Illicit
DronedaroneThe metabolism of Ondansetron can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Drotebanol.Experimental, Illicit
DuloxetineOndansetron may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ondansetron.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Ondansetron is combined with Efavirenz.Approved, Investigational
EletriptanOndansetron may increase the serotonergic activities of Eletriptan.Approved, Investigational
EliglustatThe metabolism of Ondansetron can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ondansetron.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Ondansetron is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Ondansetron can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateOndansetron may increase the serotonergic activities of Ergoloid mesylate.Approved
ErgonovineOndansetron may increase the serotonergic activities of Ergonovine.Approved
ErgotamineOndansetron may increase the serotonergic activities of Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Ondansetron.Approved, Vet Approved
EscitalopramOndansetron may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ondansetron.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ondansetron.Approved
EthanolOndansetron may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ondansetron.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ondansetron.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Ondansetron can be decreased when combined with Etravirine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Ondansetron.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Ondansetron.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Ondansetron.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylOndansetron may increase the serotonergic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ondansetron.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fexofenadine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
FlecainideOndansetron may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Flibanserin.Approved
FloxuridineThe metabolism of Ondansetron can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Ondansetron can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Ondansetron can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Ondansetron can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ondansetron.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ondansetron.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ondansetron.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Ondansetron can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Ondansetron can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
FosamprenavirThe metabolism of Ondansetron can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ondansetron can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Ondansetron.Approved
FosphenytoinThe metabolism of Ondansetron can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fospropofol.Approved, Illicit
FrovatriptanOndansetron may increase the serotonergic activities of Frovatriptan.Approved, Investigational
Fusidic AcidThe serum concentration of Ondansetron can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ondansetron.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Ondansetron is combined with Gabapentin Enacarbil.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Ondansetron.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Ondansetron.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ondansetron.Approved, Illicit
GemfibrozilThe metabolism of Ondansetron can be decreased when combined with Gemfibrozil.Approved
GemifloxacinOndansetron may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineOndansetron may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Ondansetron is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Glutethimide.Approved, Illicit
GoserelinGoserelin may increase the QTc-prolonging activities of Ondansetron.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ondansetron.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Ondansetron.Approved
HalothaneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Ondansetron is combined with Hexobarbital.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Ondansetron.Approved
HydrocodoneOndansetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ondansetron.Approved, Illicit
HydroxyamphetamineOndansetron may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
IbutilideOndansetron may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Ondansetron can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Iloperidone.Approved
ImatinibThe metabolism of Ondansetron can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Ondansetron.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Ondansetron.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Ondansetron.Approved
IndinavirThe metabolism of Ondansetron can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Ondansetron is combined with Indiplon.Investigational
Iofetamine I-123Ondansetron may decrease the stimulatory activities of Iofetamine I-123.Approved
IrbesartanThe metabolism of Ondansetron can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Ondansetron can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidOndansetron may increase the serotonergic activities of Isocarboxazid.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Ondansetron.Approved, Vet Approved
IsoniazidThe metabolism of Ondansetron can be decreased when combined with Isoniazid.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Ondansetron.Approved
ItraconazoleThe metabolism of Ondansetron can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Ondansetron.Approved
IvacaftorThe serum concentration of Ondansetron can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ondansetron.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Ondansetron can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Lamotrigine.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
LeflunomideThe metabolism of Ondansetron can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibOndansetron may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levodopa.Approved
LevofloxacinOndansetron may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levomethadyl Acetate.Approved
LevomilnacipranOndansetron may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ondansetron.Approved
LidocaineThe metabolism of Ondansetron can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidOndansetron may increase the serotonergic activities of Linezolid.Approved, Investigational
LisdexamfetamineOndansetron may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Ondansetron.Approved
LobeglitazoneThe metabolism of Ondansetron can be decreased when combined with Lobeglitazone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ondansetron is combined with Lofentanil.Illicit
LopinavirThe metabolism of Ondansetron can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ondansetron.Approved
LorcaserinOndansetron may increase the serotonergic activities of Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Lormetazepam.Approved
LosartanThe metabolism of Ondansetron can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Ondansetron can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ondansetron.Approved
LuliconazoleThe serum concentration of Ondansetron can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ondansetron can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Ondansetron can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ondansetron.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved, Vet Approved
ManidipineThe metabolism of Ondansetron can be decreased when combined with Manidipine.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Ondansetron.Approved
MebicarThe risk or severity of adverse effects can be increased when Ondansetron is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Ondansetron.Approved
MelatoninThe risk or severity of adverse effects can be increased when Ondansetron is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Melperone.Approved
MephedroneOndansetron may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineOndansetron may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ondansetron.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Meptazinol.Experimental
MequitazineOndansetron may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Metaxalone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Ondansetron.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineOndansetron may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ondansetron.Approved
MethotrimeprazineOndansetron may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methoxyflurane.Approved, Vet Approved
MethoxyphenamineOndansetron may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ondansetron.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ondansetron.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Ondansetron.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Ondansetron.Approved
MetyrosineOndansetron may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Ondansetron can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ondansetron.Approved, Illicit
MidomafetamineOndansetron may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
MidostaurinThe metabolism of Ondansetron can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Ondansetron can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranOndansetron may increase the serotonergic activities of Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Ondansetron.Approved
MirtazapineOndansetron may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Ondansetron can be decreased when it is combined with Mitotane.Approved
MMDAOndansetron may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideOndansetron may increase the serotonergic activities of Moclobemide.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Ondansetron.Approved
MolindoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ondansetron.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ondansetron.Approved
NaratriptanOndansetron may increase the serotonergic activities of Naratriptan.Approved, Investigational
NefazodoneThe metabolism of Ondansetron can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ondansetron can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ondansetron can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ondansetron can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Ondansetron can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Ondansetron can be decreased when combined with Nicotine.Approved
NilotinibThe metabolism of Ondansetron can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ondansetron.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ondansetron.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Ondansetron.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Ondansetron.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
OfloxacinOndansetron may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
OlaparibThe metabolism of Ondansetron can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Ondansetron.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Ondansetron can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OpiumThe risk or severity of adverse effects can be increased when Ondansetron is combined with Opium.Approved, Illicit
OrphenadrineOndansetron may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ondansetron is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Ondansetron can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ondansetron.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Ondansetron is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ondansetron.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ondansetron.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ondansetron.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Ondansetron.Approved, Vet Approved
PalbociclibThe serum concentration of Ondansetron can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ondansetron.Approved
PanobinostatOndansetron may increase the arrhythmogenic activities of Panobinostat.Approved, Investigational
ParaldehydeOndansetron may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Ondansetron can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Ondansetron.Approved
PazopanibOndansetron may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Ondansetron can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Penfluridol.Experimental
PentamidinePentamidine may increase the QTc-prolonging activities of Ondansetron.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ondansetron.Approved, Vet Approved
PentobarbitalThe metabolism of Ondansetron can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
PerazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Perazine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Ondansetron.Approved
PerospironeThe risk or severity of adverse effects can be increased when Ondansetron is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ondansetron.Approved
PethidineOndansetron may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Phenazocine.Experimental
PhenelzineOndansetron may increase the serotonergic activities of Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Ondansetron is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Ondansetron can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Phenoxyethanol.Approved
PhentermineOndansetron may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe metabolism of Ondansetron can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ondansetron.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Ondansetron can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleOndansetron may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ondansetron.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ondansetron.Approved
PrimaquineOndansetron may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Ondansetron can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideOndansetron may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ondansetron.Approved, Investigational, Vet Approved
ProcarbazineOndansetron may increase the serotonergic activities of Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ondansetron.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Ondansetron.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Ondansetron.Approved
PropafenoneOndansetron may increase the QTc-prolonging activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Ondansetron is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ondansetron.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Propoxycaine.Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Ondansetron.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Ondansetron is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Ondansetron is combined with PSD502.Investigational
PseudoephedrineOndansetron may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe metabolism of Ondansetron can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ondansetron.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ondansetron.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Ondansetron.Approved
QuinidineThe metabolism of Ondansetron can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Ondansetron can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ramelteon.Approved, Investigational
RanolazineRanolazine may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
RasagilineOndansetron may increase the serotonergic activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ondansetron.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ondansetron.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ondansetron.Approved
RifabutinThe metabolism of Ondansetron can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ondansetron can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ondansetron can be increased when combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Ondansetron.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ritanserin.Investigational
RitobegronOndansetron may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Ondansetron can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanOndansetron may increase the serotonergic activities of Rizatriptan.Approved
RolapitantThe metabolism of Ondansetron can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Romifidine.Vet Approved
RopiniroleOndansetron may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ondansetron.Approved
RotigotineOndansetron may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ondansetron.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Ondansetron.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Ondansetron.Approved
SaquinavirOndansetron may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Ondansetron can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineOndansetron may increase the serotonergic activities of Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sertindole.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Ondansetron.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Ondansetron.Approved, Vet Approved
SildenafilThe metabolism of Ondansetron can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ondansetron can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ondansetron can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Ondansetron.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
SotalolOndansetron may increase the QTc-prolonging activities of Sotalol.Approved
St. John's WortThe serum concentration of Ondansetron can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Ondansetron can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ondansetron.Approved, Investigational
SulfadiazineThe metabolism of Ondansetron can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Ondansetron.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Ondansetron.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sultopride.Experimental
SumatriptanOndansetron may increase the serotonergic activities of Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
SuvorexantOndansetron may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenTamoxifen may increase the QTc-prolonging activities of Ondansetron.Approved
TandospironeThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tasimelteon.Approved
Tedizolid PhosphateOndansetron may increase the serotonergic activities of Tedizolid Phosphate.Approved
TelaprevirThe metabolism of Ondansetron can be decreased when combined with Telaprevir.Withdrawn
TelavancinOndansetron may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinOndansetron may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ondansetron.Approved
Tenofovir disoproxilThe metabolism of Ondansetron can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Ondansetron can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Ondansetron.Approved
TeriflunomideThe serum concentration of Ondansetron can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ondansetron.Approved
TetracaineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tetrodotoxin.Investigational
ThalidomideOndansetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Ondansetron can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Ondansetron is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ondansetron.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Ondansetron.Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Ondansetron.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tiapride.Approved, Investigational
TicagrelorThe metabolism of Ondansetron can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Ondansetron can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tilidine.Experimental
TipranavirThe metabolism of Ondansetron can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Ondansetron.Approved
TocilizumabThe serum concentration of Ondansetron can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Ondansetron can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Topiramate.Approved
TopiroxostatThe metabolism of Ondansetron can be decreased when combined with Topiroxostat.Approved
ToremifeneOndansetron may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolOndansetron may decrease the analgesic activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineOndansetron may increase the serotonergic activities of Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ondansetron.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Ondansetron is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ondansetron.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Ondansetron is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ondansetron.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Ondansetron.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Ondansetron.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Ondansetron.Approved, Vet Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ondansetron.Approved, Investigational
ValsartanThe metabolism of Ondansetron can be decreased when combined with Valsartan.Approved, Investigational
VandetanibOndansetron may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Ondansetron.Approved
VemurafenibThe serum concentration of Ondansetron can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Ondansetron.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Veralipride.Experimental
VerapamilThe metabolism of Ondansetron can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Ondansetron is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Ondansetron.Approved
VilazodoneOndansetron may increase the serotonergic activities of Vilazodone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Ondansetron is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Ondansetron can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Ondansetron.Approved, Investigational
VortioxetineOndansetron may increase the serotonergic activities of Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Ondansetron is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Ondansetron can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZafirlukastThe metabolism of Ondansetron can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ondansetron.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ondansetron can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zolazepam.Vet Approved
ZolmitriptanOndansetron may increase the serotonergic activities of Zolmitriptan.Approved, Investigational
ZolpidemOndansetron may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ondansetron.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zotepine.Approved
ZucapsaicinThe metabolism of Ondansetron can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ondansetron.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Peter Bod, Kalman Harsanyi, Ferenc Trischler, Eva Fekecs, Attila Csehi, Bela Hegedus, Eva Mersich nee Donat, Gyorgyi Szabo nee Komlosi, Erika Horvath nee Sziki, "Process for preparing ondansetron." U.S. Patent US5478949, issued September, 1990.

US5478949
General References
  1. Ramsook C, Sahagun-Carreon I, Kozinetz CA, Moro-Sutherland D: A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med. 2002 Apr;39(4):397-403. [PubMed:11919526]
  2. Yilmaz HL, Yildizdas RD, Sertdemir Y: Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study. Aliment Pharmacol Ther. 2010 Jan;31(1):82-91. doi: 10.1111/j.1365-2036.2009.04145.x. Epub . [PubMed:19758398]
  3. Gregory RE, Ettinger DS: 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89. [PubMed:9506240]
  4. Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38. [PubMed:15740177]
External Links
Human Metabolome Database
HMDB05035
KEGG Drug
D00456
KEGG Compound
C07325
PubChem Compound
4595
PubChem Substance
46504819
ChemSpider
4434
BindingDB
85330
ChEBI
7773
ChEMBL
CHEMBL46
Therapeutic Targets Database
DAP000221
PharmGKB
PA450705
IUPHAR
2290
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Ondansetron
ATC Codes
A04AA01 — Ondansetron
AHFS Codes
  • 56:22.20
PDB Entries
Not Available
FDA label
Download (126 KB)
MSDS
Download (53.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedSupportive CareNausea / Vomiting1
0CompletedTreatmentDyspnea1
0RecruitingSupportive CareNausea / Vomiting1
1Active Not RecruitingNot AvailableAAT Deficiency / AATD / Alpha-1 Antitrypsin Deficiency / Fibrosis, Liver1
1CompletedNot AvailableHealthy Volunteers9
1CompletedBasic ScienceBrain Function / Healthy Adults1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedDiagnosticAlcoholism1
1CompletedOtherNausea and Vomiting, Postoperative / Prophylaxis of acute chemotherapy induced nausea and vomiting1
1CompletedTreatmentConcussion, Brain / Traumatic Brain Injury (TBI)1
1CompletedTreatmentFasting State1
1CompletedTreatmentFed1
1CompletedTreatmentGastroenteritis1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Tumors, Solid1
1CompletedTreatmentNausea3
1CompletedTreatmentNausea / Vomiting2
1CompletedTreatmentProphylaxis against postoperative nausea and vomiting1
1CompletedTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting3
1RecruitingTreatmentTumors, Solid1
1TerminatedNot AvailableSchizophrenic Disorders1
1TerminatedTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting1
1Unknown StatusTreatmentPsychosis Not Otherwise Specified / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
1, 2CompletedNot AvailableProphylaxis against postoperative nausea and vomiting1
2Active Not RecruitingTreatmentAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentAlcohol Abuse / Alcoholism1
2Active Not RecruitingTreatmentNausea / Vomiting1
2CompletedPreventionCINV1
2CompletedPreventionProphylaxis against postoperative nausea and vomiting1
2CompletedPreventionProphylaxis of acute chemotherapy induced nausea and vomiting1
2CompletedSupportive CareAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Atypical Chronic Myeloid Leukemia, BCR-ABL Negative / Blastic Phase Chronic Myelogenous Leukemia / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Disseminated Neuroblastoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Poor Prognosis Metastatic Gestational Trophoblastic Tumor / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Neuroblastoma / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage II Ovarian Epithelial Cancer / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Malignant Testicular Germ Cell Tumor / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Ovarian Epithelial Cancer / Stage III Small Lymphocytic Lymphoma / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Breast Cancer / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Ovarian Epithelial Cancer / Stage IV Small Lymphocytic Lymphoma1
2CompletedSupportive CareAcute Myelogenous Leukaemia (AML) / Prophylaxis of acute chemotherapy induced nausea and vomiting1
2CompletedSupportive CareNausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedSupportive CareNausea / Vomiting1
2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Chronic Myelogenous Leukemia (CML) / Hematologic Diseases / Myelodysplastic Syndrome1
2CompletedTreatmentAlcohol Abuse / Alcohol Dependence1
2CompletedTreatmentAlcohol Dependence1
2CompletedTreatmentAlcoholism2
2CompletedTreatmentAmphetamine-Related Disorders1
2CompletedTreatmentCardiac Output1
2CompletedTreatmentChemotherapy-Induced / Nausea and Vomiting1
2CompletedTreatmentCocaine-Related Disorders / Drug Administration Schedule1
2CompletedTreatmentDependence, Cocaine / Methamphetamine Dependence1
2CompletedTreatmentNausea and Vomiting1
2CompletedTreatmentNausea and Vomiting, Postoperative / Prophylaxis against postoperative nausea and vomiting1
2CompletedTreatmentPost-Operative Nausea / Post-Operative Vomiting1
2CompletedTreatmentProphylaxis against postoperative nausea and vomiting3
2CompletedTreatmentPsychosis Not Otherwise Specified / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
2CompletedTreatmentTobacco Use Disorders1
2CompletedTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting2
2Not Yet RecruitingTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting1
2RecruitingPreventionDrug withdrawal syndrome neonatal / Narcotic Addiction1
2RecruitingSupportive CareChemo-radiation Induced Nausea and Vomiting1
2RecruitingSupportive CareSarcomas1
2RecruitingTreatmentAlcohol Use Disorder (AUD)1
2RecruitingTreatmentGliomas / Nausea / Vomiting1
2TerminatedSupportive CareNausea / Unspecified Childhood Solid Tumor, Protocol Specific / Vomiting1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentObsessive-Compulsive Disorder (OCD)1
2Unknown StatusTreatmentAlcoholism1
2Unknown StatusTreatmentCancer, Breast1
2Unknown StatusTreatmentDependence, Cocaine1
2WithdrawnSupportive CareAdverse Effects / Mycobacterium avium complex infection1
2WithdrawnSupportive CareMalignant Gliomas1
2, 3Not Yet RecruitingTreatmentAlcoholism1
2, 3RecruitingTreatmentGastroenteritis1
2, 3Unknown StatusPreventionArterial Hypotension / Pregnancy1
3Active Not RecruitingTreatmentCancer of the Cervix1
3CompletedNot AvailableBioavailability1
3CompletedPreventionNausea / Prophylaxis of acute chemotherapy induced nausea and vomiting / Vomiting1
3CompletedPreventionProphylaxis against postoperative nausea and vomiting4
3CompletedPreventionRadiotherapy Induced Nausea and Vomiting1
3CompletedPreventionVomiting1
3CompletedPreventionProphylaxis of acute chemotherapy induced nausea and vomiting6
3CompletedSupportive CareCancers1
3CompletedSupportive CareChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Nausea and Vomiting / Precancerous Conditions / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
3CompletedSupportive CareNausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedSupportive CareNausea and Vomiting / Prophylaxis of acute chemotherapy induced nausea and vomiting1
3CompletedTreatmentAcute Gastroenteritis / Gastroenteritis / Vomiting1
3CompletedTreatmentAlcohol Dependence1
3CompletedTreatmentAlcoholism1
3CompletedTreatmentAnaesthesia therapy1
3CompletedTreatmentBioavailability1
3CompletedTreatmentInteraction Between Antiemetic Drugs and Paracetamol1
3CompletedTreatmentNausea / Prophylaxis of acute chemotherapy induced nausea and vomiting / Vomiting1
3CompletedTreatmentPain1
3CompletedTreatmentProphylaxis against postoperative nausea and vomiting1
3CompletedTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting1
3Not Yet RecruitingPreventionAdjunct to general anesthesia therapy / Anaesthesia therapy / Analgesics / Analgesics, Opioid / Dexmedetomidine / Gabapentin / Ketamine / Lidocaine / Narcotics / Obstructive Sleep Apnea of Child / Oximetry, Pulse / Pathologic Processes / Physiologic Effects of Drugs / Postoperative Complications / Respiratory Depression / Sleep Disordered Breathing (SDB) / Tonsillectomy1
3Not Yet RecruitingSupportive CareProphylaxis of acute chemotherapy induced nausea and vomiting1
3Not Yet RecruitingTreatmentAcute Gastroenteritis / Vomiting1
3RecruitingPreventionChemotherapy Induced Vomiting / Leukemia Acute Myeloid Leukemia (AML)1
3RecruitingPreventionChildhood Cancers / Nausea / Vomiting1
3RecruitingSupportive CareBreast - Female1
3RecruitingTreatmentSchizoaffective and Schizophreniform Disorders / Schizophrenic Disorders1
3TerminatedPreventionProphylaxis of acute chemotherapy induced nausea and vomiting1
3TerminatedTreatmentGastroenteritis / Vomiting1
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3Unknown StatusSupportive CareCancers / Malignancies1
3WithdrawnSupportive CareCancers / Nausea and Vomiting / Prophylaxis of acute chemotherapy induced nausea and vomiting / Solid Tumor Cancers1
4Active Not RecruitingTreatmentVomiting1
4CompletedPreventionCardiac Repolarization1
4CompletedPreventionMaternal Hypotension1
4CompletedPreventionNausea / Postoperative Nausea and Vomiting (PONV)1
4CompletedPreventionNausea / Satisfaction / Vomiting1
4CompletedPreventionNausea / Vomiting1
4CompletedPreventionPonv1
4CompletedPreventionProphylaxis against postoperative nausea and vomiting8
4CompletedPreventionGallstone formation1
4CompletedTreatmentAnaesthetics Gases, Xenon / Anaesthetics Volatile, Sevoflurane / Depth of Anaesthesia / Prophylaxis against postoperative nausea and vomiting1
4CompletedTreatmentAnalgesics / Pain, Chronic / Postoperative pain1
4CompletedTreatmentChemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)1
4CompletedTreatmentChlorzoxazone / Postoperative pain1
4CompletedTreatmentDehydration / Diarrhea / Gastroenteritis / Vomiting1
4CompletedTreatmentDrug Overdose1
4CompletedTreatmentGall Stone Disease1
4CompletedTreatmentHeadaches1
4CompletedTreatmentIrritable Bowel Syndrome With Diarrhoea1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain1
4CompletedTreatmentNausea and Vomiting, Postoperative1
4CompletedTreatmentNausea / Vomiting3
4CompletedTreatmentObsessive Compulsive Disorder (OCD)2
4CompletedTreatmentPain1
4CompletedTreatmentPostoperative Function Level / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
4CompletedTreatmentPostoperative pain1
4CompletedTreatmentProlonged QTc Interval1
4CompletedTreatmentProphylaxis against postoperative nausea and vomiting1
4Enrolling by InvitationTreatmentAnesthesia Complication / Hemodynamics Instability / Ileus paralytic / Nausea / Postoperative pain / Vomiting1
4Not Yet RecruitingPreventionProphylaxis against postoperative nausea and vomiting2
4Not Yet RecruitingPreventionPruritus1
4Not Yet RecruitingTreatmentCannabis Use Disorders1
4Not Yet RecruitingTreatmentInguinal Hernias / Postoperative pain1
4RecruitingPreventionAnesthesia, Pediatrics, Surgery1
4RecruitingPreventionArterial Hypotension1
4RecruitingPreventionFractures, Bone / Morphine Adverse Reaction / Nausea and Vomiting, Postoperative / Pruritus / Satisfaction, Personal1
4RecruitingSupportive CareBehaviors / Cognitive Change1
4RecruitingTreatmentAbdominal Pain (AP) / Nausea1
4RecruitingTreatmentAlcohol Use Disorder (AUD) / Bipolar Disorder (BD) / Dual Diagnosis1
4RecruitingTreatmentDehydration / Diarrhea / Gastroenteritis / Vomiting1
4RecruitingTreatmentGilles de la Tourette's Syndrome / Obsessive-Compulsive Disorder (OCD) / Tic Disorders1
4RecruitingTreatmentNausea1
4RecruitingTreatmentProphylaxis against postoperative nausea and vomiting1
4TerminatedTreatmentTumors1
4Unknown StatusNot AvailableDependence, Cocaine1
4WithdrawnTreatmentMalignant Childhood Neoplasm1
Not AvailableActive Not RecruitingTreatmentNausea / Vomiting1
Not AvailableActive Not RecruitingTreatmentOpiate withdrawal symptoms / Physical Dependence1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableNausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableCompletedNot AvailableOndansetron1
Not AvailableCompletedOtherPain1
Not AvailableCompletedPreventionAnesthesia; Adverse Effect, Spinal and Epidural1
Not AvailableCompletedPreventionCesarean Delivery1
Not AvailableCompletedPreventionLaparoscopic Marsupialization of Renal Cyst1
Not AvailableCompletedPreventionMorphine Adverse Reaction1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting3
Not AvailableCompletedSupportive CareCancers1
Not AvailableCompletedSupportive CareMale Breast Cancer / Nausea and Vomiting / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer1
Not AvailableCompletedSupportive CareNeoplasms, Malignant1
Not AvailableCompletedTreatmentAbdominal mass1
Not AvailableCompletedTreatmentBenign Paroxysmal Positional Vertigo (BPPV)1
Not AvailableCompletedTreatmentDrug Interactions1
Not AvailableCompletedTreatmentItching1
Not AvailableCompletedTreatmentMalignant Lymphomas1
Not AvailableCompletedTreatmentMyocardial Repolarization1
Not AvailableCompletedTreatmentNeoplasms, Pancreatic1
Not AvailableCompletedTreatmentProphylaxis against postoperative nausea and vomiting1
Not AvailableCompletedTreatmentSchizophrenic Disorders2
Not AvailableCompletedTreatmentSedation, Conscious1
Not AvailableCompletedTreatmentSubstance Withdrawal Syndrome1
Not AvailableCompletedTreatmentVomiting of Pregnancy1
Not AvailableNot Yet RecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingNot AvailableAdverse Reaction to Other Drugs and Medicines1
Not AvailableRecruitingPreventionCesarean Section / Pruritus1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting2
Not AvailableRecruitingSupportive CareCancer, Breast / Prophylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingSupportive CareInguinal Hernias / Postoperative pain1
Not AvailableRecruitingSupportive CarePostoperative pain / Undescended Testis1
Not AvailableRecruitingTreatmentAdverse Anesthesia Outcome1
Not AvailableRecruitingTreatmentAnaesthesia therapy / Anesthesia Morbidity / Breast Neoplasm Female / Regional Anesthesia / Regional Anesthesia Morbidity1
Not AvailableRecruitingTreatmentDrug-induced Nausea and Vomiting1
Not AvailableRecruitingTreatmentNausea1
Not AvailableRecruitingTreatmentRectal Carcinoma1
Not AvailableTerminatedPreventionArterial Hypotension1
Not AvailableTerminatedTreatmentNausea1
Not AvailableUnknown StatusPreventionArterial Hypotension / Nausea and Vomiting / Shivering / Vasopressor1
Not AvailableUnknown StatusPreventionNausea and Vomiting1
Not AvailableUnknown StatusSupportive CareNon-Hodgkin's Lymphoma (NHL)1
Not AvailableUnknown StatusTreatmentDependence, Cocaine / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableUnknown StatusTreatmentPost Operative Nausea and Vomiting (PONV) / Rescue Emetic Therapy1
Not AvailableUnknown StatusTreatmentSedation and Analgesia / Side Effect of Drug1
Not AvailableUnknown StatusTreatmentSubstance-Related Disorders1
Not AvailableWithdrawnPreventionPolymorphism, Genetic / Prophylaxis against postoperative nausea and vomiting1
Not AvailableWithdrawnPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableWithdrawnPreventionRespiratory Complications / Swallowing Disorders1
Not AvailableWithdrawnSupportive CareLeukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myeloproliferative Disorders / Nausea and Vomiting / Tumors, Solid1
Not AvailableWithdrawnTreatmentDehydration / Gastroenteritis1

Pharmacoeconomics

Manufacturers
  • Par pharmaceutical
  • Aurobindo pharma ltd
  • Barr laboratories inc
  • Glenmark generics ltd
  • Kv pharmaceutical co
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Glaxosmithkline
  • Akorn strides llc
  • Apotex inc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Emcure pharmaceuticals ltd
  • Gland pharma ltd
  • Hikma farmaceutica (portugal) sa
  • Hospira inc
  • Lannett holdings inc
  • Luitpold pharmaceuticals inc
  • Pharmaforce inc
  • Pliva hrvatska doo
  • Sandoz canada inc
  • Spectrum pharmaceuticals
  • Wockhardt ltd
  • Bedford laboratories
  • Claris lifesciences ltd
  • Teva parenteral medicines inc
  • Baxter healthcare corp
  • Apotex inc richmond hill
  • Taro pharmaceuticals ireland ltd
  • Roxane laboratories inc
  • Taro pharmaceutical industries ltd
  • Dr reddys laboratories ltd
  • Natco pharma ltd
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
InjectionIntramuscular; Intravenous2 mg/mL
Injection, solutionIntramuscular2 mg/mL
Injection, solutionIntramuscular; Intravenous4 mg/2mL
SolutionOral4 mg/5mL
SolutionOral4 mg
TabletOral24 mg/1
TabletOral4 mg/1
TabletOral8 mg/1
Tablet, film coatedOral4 mg/1
Tablet, coatedOral4 mg/31
InjectionIntravenous2 mg/mL
Injection, solutionIntramuscular; Intravenous2 mg/mL
Injection, solutionIntravenous2 mg/mL
SolutionIntramuscular; Intravenous2 mg/mL
SolutionIntravenous2 mg/mL
Tablet, film coatedOral24 mg/1
Tablet, film coatedOral8 mg/1
Injection, solutionIntravenous32 mg/50mL
SolutionIntravenous2 mg
SolutionIntravenous2.00 mg
Film, solubleOral4 mg
Film, solubleOral8 mg
TabletOral4 mg
TabletOral8 mg
Tablet, orally disintegratingOral4 mg
Tablet, orally disintegratingOral8 mg
LiquidIntravenous2 mg
Tablet, orally disintegratingOral4 mg/1
Tablet, orally disintegratingOral8 mg/1
FilmOral4 mg/1
FilmOral8 mg/1
Film, solubleOral4 mg/1
Film, solubleOral8 mg/1
Prices
Unit descriptionCostUnit
Ondansetron 30 8 mg Dispersible Tablet Box1158.51USD box
Zofran ODT 30 4 mg Dispersible Tablet Box782.26USD box
Ondansetron 30 4 mg Dispersible Tablet Box695.53USD box
Ondansetron hcl powder177.0USD g
Ondansetron hcl 24 mg tablet105.5USD tablet
Zofran 8 mg tablet45.16USD tablet
Zofran odt 8 mg tablet41.76USD tablet
Ondansetron hcl 8 mg tablet40.75USD tablet
Ondansetron odt 8 mg tablet37.13USD tablet
Zofran 4 mg tablet27.11USD tablet
Ondansetron hcl 4 mg tablet25.07USD tablet
Zofran odt 4 mg tablet25.07USD tablet
Zofran 8 mg Tablet23.02USD tablet
Zofran Odt 8 mg Disintegrating Tablet22.49USD tablet
Ondansetron odt 4 mg tablet22.3USD tablet
Zofran 4 mg Tablet15.09USD tablet
Zofran Odt 4 mg Disintegrating Tablet14.74USD tablet
Zofran 2 mg/ml vial12.82USD ml
Zofran 4 mg/2 ml vial12.82USD ml
Apo-Ondansetron 8 mg Tablet12.06USD tablet
Co Ondansetron 8 mg Tablet12.06USD tablet
Jamp-Ondansetron 8 mg Tablet12.06USD tablet
Mint-Ondansetron 8 mg Tablet12.06USD tablet
Mylan-Ondansetron 8 mg Tablet12.06USD tablet
Novo-Ondansetron 8 mg Tablet12.06USD tablet
Ondansetron-Odan 8 mg Tablet12.06USD tablet
Phl-Ondansetron 8 mg Tablet12.06USD tablet
Pms-Ondansetron 8 mg Tablet12.06USD tablet
Ran-Ondansetron 8 mg Tablet12.06USD tablet
Ratio-Ondansetron 8 mg Tablet12.06USD tablet
Sandoz Ondansetron 8 mg Tablet12.06USD tablet
Zofran 2 mg/ml11.12USD ml
Apo-Ondansetron 4 mg Tablet7.9USD tablet
Co Ondansetron 4 mg Tablet7.9USD tablet
Jamp-Ondansetron 4 mg Tablet7.9USD tablet
Mint-Ondansetron 4 mg Tablet7.9USD tablet
Mylan-Ondansetron 4 mg Tablet7.9USD tablet
Novo-Ondansetron 4 mg Tablet7.9USD tablet
Ondansetron-Odan 4 mg Tablet7.9USD tablet
Phl-Ondansetron 4 mg Tablet7.9USD tablet
Pms-Ondansetron 4 mg Tablet7.9USD tablet
Ran-Ondansetron 4 mg Tablet7.9USD tablet
Ratio-Ondansetron 4 mg Tablet7.9USD tablet
Sandoz Ondansetron 4 mg Tablet7.9USD tablet
Ondansetron (Preservative Free) 2 mg/ml6.23USD ml
Ondansetron (Preserved) 2 mg/ml6.23USD ml
Ondansetron (Unpreserved) 2 mg/ml6.23USD ml
Ondansetron (With Preservative) 2 mg/ml6.23USD ml
Ondansetron Omega (Preservative Free) 2 mg/ml6.23USD ml
Ondansetron Omega (With Preservative) 2 mg/ml6.23USD ml
Ondansetron hcl 4 mg/2 ml vial3.13USD ml
Zofran 0.8 mg/ml Solution2.3USD ml
Apo-Ondansetron 0.8 mg/ml Solution1.53USD ml
Ondansetron 32 mg/50 ml bag0.86USD ml
Ondansetron hcl 32 mg/50 ml bg0.42USD ml
Ondansetron 40 mg/20 ml vial0.17USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5344658No1994-09-062011-09-06Us
CA2205600No2000-05-302015-11-20Canada
US5955488Yes1996-05-142016-05-14Us
US6063802Yes1996-05-142016-05-14Us
US5854270Yes1996-05-202016-05-20Us
US9095577No2010-07-132030-07-13Us
US8580830No2009-11-232029-11-23Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.248 mg/mLALOGPS
logP2.56ALOGPS
logP2.35ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)15.39ChemAxon
pKa (Strongest Basic)7.34ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area39.82 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity86.78 m3·mol-1ChemAxon
Polarizability33.16 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.9882
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7019
P-glycoprotein inhibitor IInhibitor0.5833
P-glycoprotein inhibitor IIInhibitor0.8807
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.7456
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.647
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5954
Ames testNon AMES toxic0.5463
CarcinogenicityNon-carcinogens0.9676
BiodegradationNot ready biodegradable0.9884
Rat acute toxicity2.4555 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7054
hERG inhibition (predictor II)Inhibitor0.7926
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0590000000-1c293e5af06aedfb74e1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-006x-0790000000-39dfc83ad8c54c21d83d
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Carbazoles
Direct Parent
Carbazoles
Alternative Parents
N-alkylindoles / Indoles / Aryl alkyl ketones / N-substituted imidazoles / N-methylpyrroles / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
Carbazole / N-alkylindole / Indole / Aryl ketone / Aryl alkyl ketone / N-methylpyrrole / N-substituted imidazole / Substituted pyrrole / Benzenoid / Imidazole
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
carbazoles (CHEBI:7773)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Artaiz I, Zazpe A, Del Rio J: Characterization of serotonergic mechanisms involved in the behavioural inhibition induced by 5-hydroxytryptophan in a modified light-dark test in mice. Behav Pharmacol. 1998 Mar;9(2):103-12. [PubMed:10065930]
  2. Fortuno A, Ballaz S, Del Rio J, Barber A: CCK-mediated response in the activation of 5-HT receptor types in the guinea-pig ileum. J Physiol Biochem. 1999 Jun;55(2):85-92. [PubMed:10517265]
  3. Llacer JM, Gallardo V, Delgado R, Parraga J, Martin D, Ruiz MA: X-ray diffraction and electron microscopy in the polymorphism study of ondansetron hydrochloride. Drug Dev Ind Pharm. 2001 Oct;27(9):899-908. [PubMed:11763467]
  4. Carvalho F, Macedo D, Bandeira I, Maldonado I, Salles L, Azevedo MF, Rocha MA Jr, Fregoneze JB, De Castro-e-Silva E: Central 5-HT3 receptor stimulation by m-CPBG increases blood glucose in rats. Horm Metab Res. 2002 Feb;34(2):55-61. [PubMed:11972287]
  5. Arcioni R, della Rocca M, Romano S, Romano R, Pietropaoli P, Gasparetto A: Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans. Anesth Analg. 2002 Jun;94(6):1553-7, table of contents. [PubMed:12032025]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Gallardo Lara V, Gallardo ML, Morales Hernandez ME, Ruiz Martinez MA: Ondansetron: design and development of oral pharmaceutical suspensions. Pharmazie. 2009 Feb;64(2):90-3. [PubMed:19320280]
  8. Mohan KC, Ravikumar K: Ondansetron hydrochloride: a competitive serotonin 5-HT3 receptor blocker. Acta Crystallogr C. 1995 Dec 15;51 ( Pt 12):2627-9. [PubMed:8588861]
  9. Dimitrov DH: Effect of Ondansetron, a 5-HT(3) receptor antagonist, on fatigue in 2 veterans with hepatitis C. Prim Care Companion J Clin Psychiatry. 2009;11(6):366-7. doi: 10.4088/PCC.08l00755. [PubMed:20098535]
  10. Szajewska H, Gieruszczak-Bialek D, Dylag M: Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children. Aliment Pharmacol Ther. 2007 Feb 15;25(4):393-400. [PubMed:17269994]
  11. Ramsook C, Sahagun-Carreon I, Kozinetz CA, Moro-Sutherland D: A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med. 2002 Apr;39(4):397-403. [PubMed:11919526]
  12. Gregory RE, Ettinger DS: 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89. [PubMed:9506240]
  13. Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38. [PubMed:15740177]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR4
Uniprot ID
Q13639
Uniprot Name
5-hydroxytryptamine receptor 4
Molecular Weight
43760.975 Da
References
  1. van Wijngaarden I, Tulp MT, Soudijn W: The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990 Jun 12;188(6):301-12. [PubMed:2164935]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. van Wijngaarden I, Tulp MT, Soudijn W: The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990 Jun 12;188(6):301-12. [PubMed:2164935]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. van Wijngaarden I, Tulp MT, Soudijn W: The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990 Jun 12;188(6):301-12. [PubMed:2164935]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. van Wijngaarden I, Tulp MT, Soudijn W: The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990 Jun 12;188(6):301-12. [PubMed:2164935]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Janicki PK: Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8. Epub 2005 Sep 26. [PubMed:16192915]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on October 20, 2017 23:43